Literature DB >> 22614014

Macrophage cathepsin K promotes prostate tumor progression in bone.

M K Herroon1, E Rajagurubandara, D L Rudy, A Chalasani, A L Hardaway, I Podgorski.   

Abstract

Bone marrow macrophages (BMMs) share common progenitors with osteoclasts and are critical components of bone-tumor microenvironment; however, their function in prostate tumor growth in the skeleton has not been explored. BMMs are the major source of inflammatory factors and proteases, including cysteine protease cathepsin K (CTSK). In this study, utilizing mice deficient in CTSK, we demonstrate the critical involvement of this potent collagenase in tumor progression in bone. We present the evidence that tumor growth and progression in the bone are impaired in the absence of CTSK. Most importantly, we show for the first time that BMM-supplied CTSK may be involved in CCL2- and COX-2-driven pathways that contribute to tumor progression in bone. Together, our data unravel novel roles for CTSK in macrophage-regulated processes, and provide evidence for close interplay between inflammatory, osteolytic and tumor cell-driven events in the bone-tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614014      PMCID: PMC3913739          DOI: 10.1038/onc.2012.166

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  83 in total

Review 1.  Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Authors:  Richard J Lee; Philip J Saylor; Matthew R Smith
Journal:  Clin Genitourin Cancer       Date:  2010-12-01       Impact factor: 2.872

Review 2.  Proteolytic networks in cancer.

Authors:  Steven D Mason; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2011-01-12       Impact factor: 20.808

3.  Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K.

Authors:  R Kiviranta; J Morko; H Uusitalo; H T Aro; E Vuorio; J Rantakokko
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

4.  Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.

Authors:  B D Gelb; G P Shi; H A Chapman; R J Desnick
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

Review 5.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

7.  Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats.

Authors:  C Andersen; C M Bagi; S W Adams
Journal:  J Musculoskelet Neuronal Interact       Date:  2003-06       Impact factor: 2.041

8.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Authors:  Vasilena Gocheva; Hao-Wei Wang; Bedrick B Gadea; Tanaya Shree; Karen E Hunter; Alfred L Garfall; Tara Berman; Johanna A Joyce
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

9.  Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.

Authors:  Sylvie Desmarais; Frédéric Massé; M David Percival
Journal:  Biol Chem       Date:  2009-09       Impact factor: 3.915

10.  The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells.

Authors:  Dong Suk Yoon; Je Hyun Yoo; Yun Hee Kim; Seungil Paik; Chang Dong Han; Jin Woo Lee
Journal:  Stem Cells Dev       Date:  2010-10       Impact factor: 3.272

View more
  31 in total

1.  A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.

Authors:  Liang Hao; Wei Chen; Matthew McConnell; Zheng Zhu; Sheng Li; Michael Reddy; Paul D Eleazer; Min Wang; Yi-Ping Li
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

2.  Photoactivated inhibition of cathepsin K in a 3D tumor model.

Authors:  Mackenzie K Herroon; Rajgopal Sharma; Erandi Rajagurubandara; Claudia Turro; Jeremy J Kodanko; Izabela Podgorski
Journal:  Biol Chem       Date:  2016-06-01       Impact factor: 3.915

Review 3.  Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

Authors:  Leah M Cook; Gemma Shay; Arturo Araujo; Arturo Aruajo; Conor C Lynch
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 4.  Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Authors:  Aimalie L Hardaway; Mackenzie K Herroon; Erandi Rajagurubandara; Izabela Podgorski
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma.

Authors:  Wenxue Hu; Yunjuan Qian; Feng Yu; Wei Liu; Yanhua Wu; Xiaowu Fang; Wenke Hao
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

Review 6.  New therapeutic targets for cancer bone metastasis.

Authors:  Jing Y Krzeszinski; Yihong Wan
Journal:  Trends Pharmacol Sci       Date:  2015-05-09       Impact factor: 14.819

7.  Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.

Authors:  F Bengsch; A Buck; S C Günther; J R Seiz; M Tacke; D Pfeifer; D von Elverfeldt; L Sevenich; L E Hillebrand; U Kern; M Sameni; C Peters; B F Sloane; T Reinheckel
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

8.  Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.

Authors:  Ulka N Vaishampayan; Izabela Podgorski; Lance K Heilbrun; Jawana M Lawhorn-Crews; Kimberlee C Dobson; Julie Boerner; Karri Stark; Daryn W Smith; Elisabeth I Heath; Joseph A Fontana; Anthony F Shields
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

Review 9.  Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors.

Authors:  Yusuke Shiozawa; Matthew R Eber; Janice E Berry; Russell S Taichman
Journal:  Bonekey Rep       Date:  2015-05-20

10.  Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.

Authors:  Tomasz Respondek; Rajgopal Sharma; Mackenzie K Herroon; Robert N Garner; Jessica D Knoll; Eric Cueny; Claudia Turro; Izabela Podgorski; Jeremy J Kodanko
Journal:  ChemMedChem       Date:  2014-04-11       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.